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Abstract
Introduction The use of noninvasive positive-pressure
mechanical ventilation (NPPV) has been investigated in several
acute respiratory failure situations. Questions remain about its
benefits when used in weaning patients from invasive
mechanical ventilation (IMV). The objective of this study was to
evaluate the use of bi-level NPPV for patients who fail weaning
from IMV.
Methods This experimental randomized clinical trial followed up
patients undergoing IMV weaning, under ventilation for more
than 48 hours, and who failed a spontaneous breathing T-piece
trial. Patients with contraindications to NPPV were excluded.
Before T-piece placement, arterial gases, maximal inspiratory
pressure, and other parameters of IMV support were measured.
During the trial, respiratory rate, tidal volume, minute volume,
rapid shallow breathing index, heart rate, arterial blood pressure,
and peripheral oxygen saturation were measured at 1 and 30
minutes. After failing a T-piece trial, patients were randomly
divided in two groups: (a) those who were extubated and placed
on NPPV and (b) those who were returned to IMV. Group results
were compared using the Student t test and the chi-square test.
Results Of 65 patients who failed T-piece trials, 28 were placed
on NPPV and 37 were placed on IMV. The ages of patients in
the NPPV and IMV groups were 67.6 ± 15.5 and 59.7 ± 17.6
years, respectively. Heart disease, post-surgery respiratory
failure, and chronic pulmonary disease aggravation were the
most frequent causes of IMV use. In both groups, ventilation
time before T-piece trial was 7.3 ± 4.1 days. Heart and
respiratory parameters were similar for the two groups at 1 and
30 minutes of T-piece trial. The percentage of complications in
the NPPV group was lower (28.6% versus 75.7%), with lower
incidences of pneumonia and tracheotomy. Length of stay in the
intensive care unit and mortality were not statistically different
when comparing the groups.
Conclusion The results suggest that NPPV is a good alternative
for ventilation of patients who fail initial weaning attempts. NPPV
reduces the incidence of pneumonia associated with
mechanical ventilation and the need for tracheotomy.
Trial registration CEP HCPA (02–114).
Introduction
Several complications may occur during invasive mechanical
ventilation (IMV), the most important of which is pneumonia
associated with mechanical ventilation [1]. To avoid tracheal
intubation and its complications, noninvasive positive-pressure
mechanical ventilation (NPPV) has been suggested as an
alternative for the management of patients with acute respira-
tory failure (ARF), particularly during the course of acute
ARF = acute respiratory failure; bpm = beats per minute; COPD = chronic obstructive pulmonary disease; CPIS = clinical pulmonary infection score; 
DBP = diastolic blood pressure; FiO2 = fraction of inspired oxygen; HR = heart rate; ICU = intensive care unit; IMV = invasive mechanical ventilation; 
MODS = multiple organ dysfunction syndrome; NPPV = noninvasive positive-pressure mechanical ventilation; PaCO2 = arterial partial pressure of 
carbon dioxide; PaO2 = arterial partial pressure of oxygen; PEEP = positive end-expiratory pressure; PImax = maximal inspiratory pressure; PTPdi = 
diaphragmatic pressure-time product; f = respiratory rate; f/VT = respiratory rate to tidal volume ratio; SBP = systolic blood pressure; SBT = sponta-
neous breathing T-piece trial; SIRS = systemic inflammatory response syndrome; SpO2 = peripheral oxygen saturation; Ve = minute volume; VT = tidal 
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pulmonary edema and chronic obstructive pulmonary disease
(COPD) [2-8].
One third of IMV time is spent in weaning, defined as the proc-
ess of gradual removal of mechanical ventilation support
toward spontaneous ventilation [9]. Most patients are weaned
with no difficulties. However, a significant percentage (5% to
30%) of patients in intensive care units (ICUs) fail spontane-
ous ventilation trials, characterizing difficult weaning [10]. In
the last few years, NPPV has been tested in these situations.
Nava and colleagues [11], in a randomized clinical trial, used
NPPV or IMV in 50 patients with COPD aggravation who
failed spontaneous ventilation trials. The authors found shorter
ventilation time and lower mortality with the use of NPPV.
Girault and colleagues [12] compared NPPV with pressure
support ventilation in 33 COPD patients who failed a 2-hour
T-piece trial and found a reduction in total mechanical ventila-
tion time in the NPPV group. However, remaining time in the
ICU and survival rates at 3 months were similar in the two
groups. Vitacca and colleagues [13] assessed diaphragm
energy expenditure (diaphragmatic pressure-time product
[PTPdi]), lung resistance and elastance, arterial blood gases,
and dyspnea during invasive and noninvasive pressure sup-
port ventilation. They found that, in patients with COPD who
were not ready to sustain spontaneous breathing, the use of
invasive or noninvasive ventilation was equally effective in
reducing PTPdi and improving arterial blood gases but that
noninvasive ventilation seemed to be better tolerated. In a later
study, Ferrer and colleagues [14] suggested that NPPV be
assessed as a means to facilitate IMV weaning for patients
who failed spontaneous ventilation trials, regardless of the
underlying disease. They confirmed the results of the previous
study and additionally reported a reduction in remaining hospi-
talization time and in the need for tracheotomy. Later, a meta-
analysis revealed that NPPV facilitates weaning and reduces
mortality comparatively to IMV [15]. Quite recently, another
two studies showed that the early use of NPPV was efficient
in preventing respiratory failure after tracheal extubation in
patients at risk for complications and that it reduced mortality
in the ICU [16,17]. In all of those trials, most patients had
COPD.
Studies assessing NPPV in weaning are still insufficient and
generally include a small number of patients. Therefore, ques-
tions remain about NPPV benefits in weaning, particularly in
heterogeneous groups of patients, which is a usual character-
istic of patients admitted to the ICU. Therefore, new controlled
and randomized studies are warranted. This study assessed
the use of NPPV during weaning from mechanical ventilation
in an ICU and compared this procedure with IMV by analyzing
cardiac and respiratory parameters, clinical course, and
complications.
Materials and methods
Population and sample
A randomized clinical trial was conducted from June 2003 to
February 2005 with patients in the ICU of Hospital de Clínicas
de Porto Alegre (Porto Alegre, Brazil). Patients of any age and
both genders were on IMV for more than 48 hours, and their
weaning procedures were followed up. Patients who failed at
30 minutes of spontaneous breathing T-piece trial (SBT) were
included in the study.
The weaning procedures followed criteria established in the
ICU routine: improvement of the cause of ARF that led to the
use of ventilation support, correction of arterial hypoxemia
(arterial partial pressure of oxygen [PaO2] of greater than 60
mm Hg), fraction of inspired oxygen (FiO2) of less than or
equal to 0.4, and positive end-expiratory pressure (PEEP) of
less than or equal to 5 cm H2O during pressure support ven-
tilation. All patients were breathing at low levels of pressure
support ventilation (less than 12 cm H2O). Patients included
in the study did not require vasoactive drugs, had an adequate
consciousness level (Glasgow coma score of greater than or
equal to 13) and cough reflex, and did not require sedation.
Failure or intolerance at 30 minutes of SBT was defined
according to one of the following criteria: peripheral oxygen
saturation (SpO2) measured by pulse oximetry of less than
90% (80% in chronic respiratory failure), respiratory rate (f) of
greater than 35 respirations per minute, heart rate (HR) of
greater than 140 or less than 50 beats per minute (bpm) (or
increase or decrease of greater than 20% in previous mechan-
ical ventilation), and systolic arterial blood pressure of greater
than 180 mm Hg or less than 70 mm Hg (or increase or
decrease of greater than 20% in previous mechanical ventila-
tion) and rapid shallow breathing index (ratio of f to tidal vol-
ume [VT], or f/VT) of greater than 105. Patients with facial
trauma, cranial surgery, recent gastric or esophageal surgery,
tracheotomy, excessive respiratory secretion, agitation, or non-
cooperative behavior were excluded from the study. This study
was approved by the Committee on Ethics on Research and
Graduate Studies of the Hospital de Clínicas de Porto Alegre.
Data collection
Patients were included in the study after an informed consent
form was signed by a family member or guardian. Patients con-
sidered apt to undergo the weaning procedure were submit-
ted to SBT. At that moment, for ICU organizational reasons,
patients had already been randomly assigned to one of the
ventilatory modes (IMV or NPPV) that would be used in case
they failed SBT. Sealed envelopes were used for random
assignment.
Before SBT, the following measurements were carried out:
arterial blood gases; parameters of IMV such as f; VT; minute
volume (Ve); inspiratory pressure peak; PEEP; FiO2; PaO2/
FiO2 ratio, and the highest value of three measurements ofAvailable online http://ccforum.com/content/12/2/R51
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maximal inspiratory pressure (PImax). PImax, defined as the max-
imal inspiratory effort sustained by the patient for 20 seconds,
by means of a unidirectional valve, allows for expiration only.
Thus, the patient had to make an inspiratory effort in order to
trigger the respiratory cycle, and PImax was measured at this
time [18,19]. This PImax was measured using a pressure vac-
uum meter (Suporte®; Porto Alegre, Brazil). At 1 minute and
30 minutes of spontaneous ventilation trial, the following
parameters were measured: f, VT, Ve, f/VT using a flowmeter
(Ohmeda, Madison, WI, USA), HR, systolic (SBP) and diasto-
lic (DBP) blood pressure, and SpO2 using a Hewlett-Packard
monitor (Hewlett-Packard Company, Palo Alto, CA, USA). If
failure occurred before the 30th minute, f, HR, SpO2, and SBP
and DBP were measured at the time of failure. If the patient
failed SBT, he/she was included in the group previously
defined by random assignment. Patients in the experimental
group were extubated and placed on NPPV, whereas the other
patients (the control group) returned to IMV, which was clas-
sified as the conventional treatment. The group on NPPV (the
experimental group) was extubated after having rested in the
mechanical ventilation for 30 minutes in the experimental
group. Immediately after tracheal extubation, spontaneous
ventilation mode using a bi-level NPPV support unit (Respiron-
ics, Synchrony, or S model; Respironics, Inc., now part of
Royal Philips Electronics N.V., Amsterdam, The Netherlands)
was used. Inspiratory positive airway pressure was delivered
according to patient tolerance and varied from 10 to 30 cm
H2O.
Expiratory positive airway pressure was set at sufficient gas
exchange maintenance level and FiO2 was set according to an
SpO2 of greater than 90%, as measured by pulse oximetry.
The interface chosen was facemask (Spectrum Reusable Full
Face Mask; Respironics, Inc.). Weaning from NPPV was per-
formed on a daily basis by gradually reducing pressure levels
until adequate VT and Ve levels could be reached and proper
alveolar ventilation could be established. In the control group,
invasive ventilation followed the previously administrated ICU
ventilation support routine using Servo 900c or Servo 300
(Siemens AG, Munich, Germany) ventilators. Daily SBT was
carried out thereafter in order to evaluate the possibility of
extubation.
Both groups were monitored using a Hewlett-Packard moni-
tor, which measured HR, f, SBP and DBP, and SpO2 by pulse
oximetry continuously. They were followed up during the first 6
hours and then evaluated every 6 to 8 hours. Arterial gases
were measured 2 hours after the patient was placed on venti-
lation and once a day until discontinuation of ventilation sup-
port. Data were collected by a team trained by one of the
authors.
During follow-up of patients receiving IMV and NPPV, other
complications were also described: pneumonia, sepsis, heart
failure, tracheotomy, reintubation, and skin necrosis. Pneumo-
nia was defined by clinical findings, new pulmonary infiltrate for
longer than 48 hours after the patient was placed on that ven-
tilation mode, and one or more of the following findings: puru-
lent tracheal secretions, fever, and leukocytosis [20-22]. The
clinical pulmonary infection score (CPIS) was also assessed
on days 0 and 3, and pneumonia was diagnosed when CPIS
was 7 or greater, according to the protocol followed in our
service [23-25]. Sepsis was defined as a systemic inflamma-
tory response syndrome (SIRS) associated with infection.
SIRS was defined as a systemic inflammatory response to sev-
eral severe clinical insults, which included two or more find-
ings such as temperature of greater than 38°C or less than
36°C, HR of greater than 90 bpm, f of greater than 20 incur-
sions per minute (ipm) or arterial partial pressure of carbon
dioxide (PaCO2) of less than 32 mm Hg, and leukocyte count
of greater than 12,000 cells per cubic millimeter, fewer than
4,000 cells per cubic millimeter, or greater than 10% of band
cells [26]. Heart failure was defined clinically and radiographi-
cally by dyspnea with rales, S3, cardiomegaly, bilateral pulmo-
nary edema, and elevated central venous pressure [27].
Tracheotomy was performed between 14 and 21 days after
the beginning of IMV, according to our service's routine.
Statistical analysis
Microsoft Excel 2000 software (Microsoft Corporation, Red-
mond, WA, USA) was used to store data. Statistical analysis
was carried out using the Statistical Package for Social Sci-
ences 12.0.1 (SPSS Inc., Chicago, IL, USA). The distribution
of continuous variable frequencies was analyzed using means
and standard deviations, which were compared using the Stu-
dent t test. Discrete variables were evaluated using a contin-
gency table and compared using the chi-square test.
Significance level was established at a P value of less than
0.05.
Results
Of the 156 patients submitted to SBT, 84 (53.8%) were ran-
domly assigned to IMV and 72 (46.2%) to NPPV. After SBT,
91 patients were successfully extubated, but 26 (29.5%) had
to be reintubated (Figure 1). Sixty-five patients (41.7%) failed
SBT and were included in this study: 28 had been randomly
assigned to NPPV and 37 to IMV. The patients in the NPPV
group tended to be older. Other clinical characteristics were
similar in the two groups. COPD aggravation, post-operative
respiratory failure, and heart disease were the most frequent
causes for the use of invasive ventilation support (Table 1) in
both groups.
The distribution of associated diseases was not significantly
different between the NPPV and IMV groups, and the most fre-
quent diseases were systemic hypertension (50% versus
27%), heart diseases (21.4% versus 21.6%), and diabetes
mellitus (17.9% versus 21.6%). Moreover, respiratory charac-
teristics of patients on mechanical ventilation, before theCritical Care    Vol 12 No 2    Trevisan et al.
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spontaneous breathing trial, were not statistically different
between the groups, as shown in Table 2.
During the spontaneous ventilation trial, 22 patients of the
NPPV group and 20 of the IMV group were able to complete
the test within 30 minutes and failed at 30 minutes, whereas 8
patients of the NPPV group and 17 of the IMV group failed
before 30 minutes. The patient's final measurements were car-
ried out at the failure moment. No statistically significant differ-
ences in cardiorespiratory parameters were found between
groups at 1 minute or at the end of the trial, as shown in Table
3. Values of SpO2 measured during ventilation support were
not statistically different between the two groups (Figure 2),
which shows that both techniques were effective in keeping
oxygenation.
The comparisons of gas measurements between the NPPV
and IMV groups showed no significant differences. The pH val-
ues were as follows: before spontaneous breathing trial, 7.41
± 0.07 for both groups; after up to 2 hours of spontaneous
breathing trial, 7.39 ± 0.06 versus 7.40 ± 0.05; after 24 hours
of ventilation support, 7.38 ± 0.08 versus 7.39 ± 0.07; and at
the end of ventilation support removal, 7.38 ± 0.06 for both
groups. PaCO2 before spontaneous ventilation trial for the two
groups was 45.1 ± 11.5 versus 40.1 ± 11.1; up to 2 hours
after failure, it was 43.2 ± 10.8 versus 41.6 ± 10.2; after 24
hours of support, it was 42.1 ± 11.3 versus 42.4 ± 11.2; and
at final removal of ventilation support, it was 41.2 ± 10.9 ver-
sus 42.2 ± 10.8. PaO2 before spontaneous ventilation trial
was 88.7 ± 23.2 versus 99.7 ± 29.5; after failure, it was 87.5
± 22.4 versus 89.8 ± 25.1; after 24 hours of ventilation sup-
port, it was 88.6 ± 24.1 versus 92.5 ± 25.6; and at the
removal of ventilation support, it was 89.2 ± 24.2 versus 95.5
± 26.2.
Table 4 compares lengths of stay in the ICU and the hospital
and mortality rate in both groups. Patients of the NPPV group
had a shorter stay in the ICU and in the hospital. Duration of
mechanical ventilation after random assignment amounted to
10.02 days for the IMV group and 7.5 days for the NPPV
group. However, these differences were not statistically signif-
icant, even though the duration of mechanical ventilation was
slightly reduced in the NPPV group. For the 6 patients
returned to IMV, duration of mechanical ventilation amounted
to 8 days. Mortality was similar in the two groups. Of the 28
patients in the NPPV group (Figure 1), 16 had no serious
complications and were not on ventilatory support when dis-
charged from the ICU. One of these patients died from pulmo-
nary embolism. Six patients returned to invasive ventilation
support because of abdominal sepsis (n = 2), worsening of
congestive heart failure (n = 3), or pneumonia (n = 1). Two of
these patients died, both due to sepsis and multiple organ dys-
function syndrome (MODS), whereas the remaining patients
were discharged. Of the 37 patients in the IMV group (Figure
Figure 1
Flowchart showing the outcome of analyzed patients Flowchart showing the outcome of analyzed patients. DHOS, ICC, ; ICU, intensive care unit; IMV, invasive mechanical ventilation; MODS, multiple 
organ dysfunction syndrome; NPPV, noninvasive positive-pressure mechanical ventilation; PNM, pneumonia; SBT, spontaneous breathing T-piece 
trial.Available online http://ccforum.com/content/12/2/R51
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1), 8 patients died in the ICU due to sepsis and MODS and 2
died from kidney failure and sepsis. Discharged patients were
not on ventilatory support when discharged from the ICU.
However, 7 patients had to undergo tracheotomy and showed
a greater incidence of complications, particularly infections.
This higher rate of complications, chiefly pneumonia, in the
IMV group, is shown in Table 5.
Discussion
The most important results of this study showed that, in
patients who failed spontaneous ventilation trial when weaning
was attempted, the combination of earlier tracheal extubation
and NPPV ventilation support is a useful alternative. They
decreased the incidence of pneumonia associated with
mechanical ventilation, as well as the need for tracheotomy, in
comparison with patients who were conventionally weaned
from IMV.
Strong evidence supports the use of NPPV to avoid place-
ment of an invasive airway and to reduce complications and
mortality due to IMV [2,28,29]. However, few randomized clin-
ical trials evaluated early use of NPPV to accelerate mechani-
Table 1
Baseline characteristics of patients who failed spontaneous breathing trial
NPPV (n = 28) IMV (n = 37) P value
Age, years 67.6 ± 15.5 59.7 ± 17.6 0.06
Gender, male/female 15/13 23/14 0.61
APACHE II score at admission 20 ± 6.8 18.0 ± 5.9 0.27
Duration of mechanical ventilation, days 7.3 ± 4.1 7.3 ± 4.1 0.98
Causes of mechanical ventilation, number (percentage)
COPD aggravation and asthma 10 (35.6%) 13 (35.1%)
Heart diseases 7 (25%) 4 (11%)
Respiratory diseases 1 (3.6%) 2 (5.4%)
Post-surgery respiratory failure 5 (18%) 11 (29.8%)
Acute pulmonary lesion 0 (0%) 2 (5.4%)
Pneumonia 3 (11%) 1 (2.7%)
Tuberculosis 1 (3.6%) 2 (5.4%)
Thoracic trauma 1 (3.6%) 1 (2.7%)
Values are mean ± standard deviation or number (percentage). P value indicates comparison between treatment groups using t test or chi-square 
test. APACHE II, Acute Physiologic And Chronic Health Evaluation II; COPD, chronic obstructive pulmonary disease; IMV, invasive mechanical 
ventilation; NPPV, noninvasive mechanical ventilation.
Table 2
Respiratory characteristics of patients before spontaneous breathing trial
NPPV (n = 28) IMV (n = 37) P value
Respiratory rate, rpm 22.3 ± 4.2 21.2 ± 4.9 0.35
Tidal volume, mL 594 ± 0.21 629 ± 0.27 0.58
Peak inspiratory pressure, cm H2O 19.3 ± 4.9 18.6 ± 2.9 0.44
Maximal inspiratory pressure, cm H2O 36.0 ± 11.5 37.0 ± 16.1 0.64
Arterial pH 7.41 ± 0.07 7.41 ± 0.06 0.96
PaCO2, mm Hg 45.1 ± 11.5 40.1 ± 11.1 0.08
PaO2, mm Hg 88.7 ± 23.2 99.7 ± 29.5 0.11
SaO2, percentage 95.8 ± 3.1 96.6 ± 2.5 0.26
Values are mean ± standard deviation. P value indicates comparison between groups using t test. IMV, invasive mechanical ventilation; NPPV, 
noninvasive mechanical ventilation; PaCO2, arterial partial pressure of carbon dioxide; PaO2, arterial partial pressure of oxygen; rpm, respirations 
per minute; SaO2, arterial saturation of oxygen.Critical Care    Vol 12 No 2    Trevisan et al.
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cal ventilation weaning. Older studies used this resource, but
it was applied at a later stage in patients ventilated for a long
time [30,31]. NPPV was recently used at earlier stages for
mechanical ventilation weaning, and the results were favora-
ble, particularly when used in selected patients, such as those
with COPD and hypercapnic respiratory failure or respiratory
acidosis [28,29]. Our study with a heterogeneous population
of patients confirmed the beneficial effects of NPPV in com-
parison with IMV during weaning.
The process of gradual removal of mechanical ventilation
poses an important clinical challenge, particularly in patients
with pulmonary diseases, and its failure rates range from 35%
to 67% [32]. Weaning failure during SBT in our study was not
an infrequent clinical situation in patients on mechanical venti-
lation for an average of 7.3 days and was observed in 41.7%
of the cases, which is in agreement with findings in the litera-
ture. Also in accordance with the literature, chronic pulmonary
diseases were the most frequent causes of mechanical venti-
lation in our patients.
The NPPV group had shorter lengths of stay in the ICU and in
the hospital, although this difference was not statistically sig-
nificant. We did not observe any reductions in mortality, as did
Ferrer and colleagues [14]. During the clinical course, the two
treatment groups showed similar gas parameters, which is
consistent with the literature [11]. In addition, there were no
statistically significant differences in cardiorespiratory param-
eters measured in the first minute and at failure of the sponta-
neous breathing trial, which indicates that the groups had very
similar baseline conditions. These findings indicate that NPPV
is at least as safe a strategy as IMV.
There were significantly fewer complications in the NPPV
group, with an important decrease in the incidence of pneumo-
nia associated with mechanical ventilation and less need for
tracheotomy. These results are similar to those of Nava and
colleagues [11] and Ferrer and colleagues [14]. As in our
study, those authors used NPPV after tracheal extubation and
maintained it as long as necessary. On the other hand, Girault
and colleagues [12] used intermittent periods of NPPV and
did not observe any significant differences in the incidence of
complications. The increased incidence of pneumonia which
is observed in cases submitted to IMV for more than 3 days is
associated with a high mortality rate [33-35]. Therefore, the
decrease in its incidence, as observed in our study, is an
important result. In addition, the decrease in the need for tra-
cheotomy may result in fewer complications. These beneficial
effects of NPPV, reducing the incidence of pneumonia and the
need for tracheotomy, may also be correlated to cost reduc-
tions, but we did not analyze this possible correlation. It is
important to note that the return to IMV of patients who did not
benefit from the use of NPPV was due to aggravation of heart
failure and abdominal sepsis and was not directly linked to the
ventilation strategy used.
One of the limitations of this study was that our sample size
was relatively small, though larger than samples in previous
studies. A study with a greater number of patients might have
yielded other significant results such as a reduction in the
Table 3
Cardiorespiratory parameters of patients during spontaneous breathing trial
NPPV (n = 28) IMV (n = 37) PA NPPV (n = 28) IMV (n = 37) PB
First minute Final
Respiratory rate (f), ipma 27.7 ± 5.7 30.05 ± 8.6 0.23 39.0 ± 2.8b 38.0 ± 3.1b 0.19
Tidal volume (VT), mL 389 ± 0.25 399 ± 0.28 0.51 278 ± 0.24b 268 ± 0.27b 0.46
f/VT 82.6 ± 45 87.6 ± 54.4 0.50 149.0 ± 67.9b 151.3 ± 58.4b 0.23
Heart rate, bpma 95.7 ± 13.6 101.4 ± 20.3 0.57 108.4 ± 12.6b 116.1 ± 14.4b 0.77
SpO2
a 95.1 ± 1.92 96.6 ± 1.97 0.15 88.2 ± 2.4 87.3 ± 2.6 0.09
Values are mean ± standard deviation. aValues at moment of failure or at 30 minutes; bP <0.05 (comparison between groups in the first and last 
minutes). bpm, beats per minute; ipm, incursions per minute; IMV, invasive mechanical ventilation; NPPV, noninvasive mechanical ventilation; PA, 
comparison between groups in the first minute (t test); PB, comparison between groups in the 30th minute (t test); SpO2, peripheral oxygen 
saturation.
Figure 2
Changes in peripheral oxygen saturation (SpO2) in the two groups of  patients Changes in peripheral oxygen saturation (SpO2) in the two groups of 
patients. CI, confidence interval; IMV, invasive mechanical ventilation; 
NPPV, noninvasive positive-pressure mechanical ventilation.Available online http://ccforum.com/content/12/2/R51
Page 7 of 8
(page number not for citation purposes)
lengths of stay in the ICU and in the hospital. Also, although it
is important to understand the role of NPPV in different groups
of patients, a stratified analysis per subgroup was not possible
because of the heterogeneity of our population as well as the
small number of patients. Another limitation was that no data
were collected after patients were discharged, and the analy-
sis of late mortality was not possible. New studies should be
carried out, with longer follow-up times and larger samples, to
evaluate the effects of NPPV on the quality of life of patients
on weaning ventilation support and to understand how the
cause of ARF could affect the results of different weaning ven-
tilation methods. Cost evaluation should also be included in
these studies.
Conclusion
The results of this study suggest that the combination of early
extubation and NPPV is a good alternative for ventilation in a
group of heterogeneous patients who initially failed weaning.
NPPV use resulted in efficient gas exchange, a tendency to
decrease ICU and hospital stays, and principally an important
reduction in the incidence of pneumonia as well as in the need
for tracheotomy when compared with conventional IMV wean-
ing. Therefore, NPPV is a useful and safe strategy that may be
considered during mechanical ventilation weaning.
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Key messages
￿  The combination of early extubation and noninvasive 
positive-pressure mechanical ventilation (NPPV) is a 
useful and safe alternative for ventilation in patients who 
fail initial weaning attempts.
￿  NPPV use resulted in efficient gas exchange, a ten-
dency to decrease intensive care unit and hospital 
stays, and principally an important reduction in the inci-
dence of pneumonia as well as in the need for tracheot-
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